Inspire Investing LLC Makes New $258,000 Investment in DexCom, Inc. $DXCM

Inspire Investing LLC acquired a new position in DexCom, Inc. (NASDAQ:DXCM) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 2,959 shares of the medical device company’s stock, valued at approximately $258,000.

A number of other institutional investors also recently made changes to their positions in the business. Nuveen LLC bought a new position in shares of DexCom during the first quarter valued at approximately $554,893,000. Jennison Associates LLC grew its stake in shares of DexCom by 37.7% in the 1st quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company’s stock worth $718,632,000 after buying an additional 2,879,489 shares during the last quarter. Massachusetts Financial Services Co. MA increased its position in DexCom by 171.0% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 3,194,829 shares of the medical device company’s stock valued at $218,175,000 after buying an additional 2,015,971 shares in the last quarter. Federated Hermes Inc. increased its position in DexCom by 2,371.4% during the 1st quarter. Federated Hermes Inc. now owns 1,994,732 shares of the medical device company’s stock valued at $136,220,000 after buying an additional 1,914,019 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in DexCom by 22.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock valued at $691,336,000 after buying an additional 1,868,241 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Activity

In other news, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $81.06, for a total value of $222,915.00. Following the sale, the director directly owned 51,121 shares in the company, valued at approximately $4,143,868.26. This represents a 5.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Sadie Stern sold 1,466 shares of the company’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $80.00, for a total transaction of $117,280.00. Following the completion of the transaction, the executive vice president owned 105,223 shares in the company, valued at approximately $8,417,840. The trade was a 1.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 6,849 shares of company stock worth $564,733 over the last 90 days. Insiders own 0.32% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on DXCM shares. Mizuho upped their target price on shares of DexCom from $95.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 16th. Raymond James Financial boosted their price objective on shares of DexCom from $99.00 to $102.00 and gave the stock a “strong-buy” rating in a report on Thursday, July 31st. Barclays increased their target price on DexCom from $93.00 to $98.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 30th. The Goldman Sachs Group reduced their target price on DexCom from $104.00 to $89.00 and set a “buy” rating for the company in a report on Wednesday, October 1st. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of DexCom in a report on Wednesday, October 8th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $97.00.

DexCom Price Performance

Shares of DexCom stock opened at $66.60 on Friday. The company has a market capitalization of $26.12 billion, a price-to-earnings ratio of 46.25, a PEG ratio of 1.39 and a beta of 1.47. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. The stock’s 50-day simple moving average is $73.35 and its 200-day simple moving average is $77.52. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $93.25.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.03. The firm had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business’s quarterly revenue was up 15.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. As a group, analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.